{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:56:41Z","timestamp":1785779801086,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Docetaxel in combination with two HER2-directed therapies, trastuzumab and pertuzumab, is the current standard frontline therapy for patients with metastatic HER2-positive breast cancer. Ado-trastuzumab (T-DM1), an antibody-drug conjugate of trastuzumab and a cytotoxic microtubule-inhibitory agent, emtansine, is approved in patients that have progressed with prior trastuzumab-based therapy. However, the benefit of T-DM1 in patients previously treated with pertuzumab therapy for metastatic breast cancer remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We identified thirty-three adults with metastatic HER2-positive breast cancer treated between March 2013 and July 2018 with T-DM1 either as subsequent therapy after progression on a pertuzumab-based regimen (i.e., \u201cpertuzumab-pretreated\u201d) or without prior exposure to pertuzumab (i.e., \u201cpertuzumab-na\u00efve\u201d). Collected data included patient demographics, treatment history, adverse events, and clinical outcomes. For both cohorts receiving T-DM1, the primary endpoint was PFS and secondary endpoints were overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR), and T-DM1-related toxicity rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Pertuzumab-pretreated patients (<jats:italic>n<\/jats:italic>\u2009=\u200923, with 21 evaluable for T-DM1 efficacy) had a median PFS of 9.5\u2009months (95% CI: 2.9\u2013NA), 1-year OS rate of 67.4% (95% CI: 50.0\u201390.9%) with an unreached median, ORR of 14.3% (95% CI: 3.0\u201336.3%), and CBR of 52.4% (95% CI: 29.8\u201374.3%), with none of these measures being statistically different than those estimated for the pertuzumab-na\u00efve group (<jats:italic>n<\/jats:italic>\u2009=\u200910). Treatment with T-DM1 after prior pertuzumab exposure (median T-DM1 duration 2.9\u2009months) resulted in no grade\u2009\u2265\u20093 adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In our cohort, prior exposure to pertuzumab did not significantly impact T-DM1\u2019s clinical efficacy or safety profile as second- or later-line therapy in patients with metastatic HER2-positive breast cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08894-2","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T10:03:43Z","timestamp":1635329023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab"],"prefix":"10.1186","volume":"21","author":[{"given":"Luai S.","family":"Al Rabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy J.","family":"Kaempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Saraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Savin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahi I.","family":"Mitri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"issue":"31","key":"8894_CR1","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane L, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8894_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/GCO.0b013e3283414e87","volume":"23","author":"R Callahan","year":"2011","unstructured":"Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol. 2011;23(1):37\u201343. https:\/\/doi.org\/10.1097\/GCO.0b013e3283414e87.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"3","key":"8894_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","volume":"17","author":"A Chan","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology. 2016;17(3):367\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(15)00551-3.","journal-title":"Lancet Oncology"},{"issue":"2","key":"8894_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast Cancer. N Engl J Med. 2017;377(2):122\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1703643.","journal-title":"N Engl J Med"},{"issue":"11","key":"8894_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast Cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392. https:\/\/doi.org\/10.1056\/NEJM200103153441101.","journal-title":"N Engl J Med"},{"issue":"16","key":"8894_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast Cancer. N Engl J Med. 2005;353(16):1673\u201384. https:\/\/doi.org\/10.1056\/NEJMoa052122.","journal-title":"N Engl J Med"},{"issue":"2","key":"8894_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med. 2012;366(2):109\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1113216.","journal-title":"N Engl J Med"},{"issue":"4","key":"8894_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology. 2020;21(4):519\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(19)30863-0.","journal-title":"The Lancet Oncology"},{"issue":"19","key":"8894_CR9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-positive advanced breast Cancer. N Engl J Med. 2012;367(19):1783\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1209124.","journal-title":"N Engl J Med"},{"issue":"7","key":"8894_CR10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop IE, Kim SB, Gonz\u00e1lez-Mart\u00edn A, LoRusso P, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2014;15(7):689\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(14)70178-0.","journal-title":"The Lancet Oncology"},{"issue":"29","key":"8894_CR11","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1200\/JCO.2016.67.3624","volume":"34","author":"H Dzimitrowicz","year":"2016","unstructured":"Dzimitrowicz H, et al. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. J Clin Oncol. 2016;34(29):3511\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8894_CR12","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.clbc.2019.09.001","volume":"20","author":"B Conte","year":"2019","unstructured":"Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D\u2019Alonzo A, et al. T-DM1 efficacy in patients with HER2-positive metastatic breast Cancer progressing after a Taxane plus Pertuzumab and Trastuzumab: an Italian multicenter observational study. Clinical Breast Cancer. 2019;20(2):e181\u20137. https:\/\/doi.org\/10.1016\/j.clbc.2019.09.001.","journal-title":"Clinical Breast Cancer"},{"issue":"4","key":"8894_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12282-019-00949-4","volume":"26","author":"S Noda-Narita","year":"2019","unstructured":"Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, et al. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Breast Cancer. 2019;26(4):492\u20138. https:\/\/doi.org\/10.1007\/s12282-019-00949-4.","journal-title":"Breast Cancer"},{"key":"8894_CR14","doi-asserted-by":"crossref","unstructured":"Krop IE, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2014:15(7): 689\u2013699.","DOI":"10.1016\/S1470-2045(14)70178-0"},{"key":"8894_CR15","doi-asserted-by":"crossref","unstructured":"Urruticoechea, A., et al., Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P). Journal of Clinical Oncology, 2017. 35(15_suppl): p. 1023\u20131023.","DOI":"10.1200\/JCO.2017.35.15_suppl.1023"},{"issue":"8","key":"8894_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, Trastuzumab, and docetaxel in HER2-positive metastatic breast Cancer. N Engl J Med. 2015;372(8):724\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1413513.","journal-title":"N Engl J Med"},{"issue":"3","key":"8894_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(18)30083-4","volume":"19","author":"H Wildiers","year":"2018","unstructured":"Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the elderly task force\/breast Cancer group. The Lancet Oncology. 2018;19(3):323\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(18)30083-4.","journal-title":"The Lancet Oncology"},{"issue":"2","key":"8894_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, et al. Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab plus Taxane for human epidermal growth factor receptor 2\u2013positive, advanced breast Cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.67.4887.","journal-title":"J Clin Oncol"},{"key":"8894_CR19","unstructured":"(NCCN), N.C.C.N., Clinical practice guidelines in oncology: breast cancer. Version 2.2020."},{"issue":"8","key":"8894_CR20","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andr\u00e9 F, et al. 4th ESO\u2013ESMO international consensus guidelines for advanced breast Cancer (ABC 4)\u2020\u2020these guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO). Ann Oncol. 2018;29(8):1634\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdy192.","journal-title":"Ann Oncol"},{"issue":"26","key":"8894_CR21","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1200\/JCO.2018.79.2697","volume":"36","author":"SH Giordano","year":"2018","unstructured":"Giordano SH, et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(26):2736\u201340.","journal-title":"J Clin Oncol"},{"issue":"7","key":"8894_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2019","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-positive metastatic breast Cancer. N Engl J Med. 2019;382(7):597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609.","journal-title":"N Engl J Med"},{"issue":"7","key":"8894_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2019","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab Deruxtecan in previously treated HER2-positive breast Cancer. N Engl J Med. 2019;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08894-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08894-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T10:05:51Z","timestamp":1635329151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08894-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8894"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08894-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OHSU\u2019s institutional review board\u2019s approval and waiver of informed consent were obtained prior to commencing the chart review (OHSU IRB #18450). All methods were carried out in accordance with relevant guidelines and regulations. OHSU\u2019s institutional review board waived the informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1150"}}